Exelixis Inc logo

Exelixis Inc

EXEL
Healthcare|Biotechnology|USA
$56.51
-0.60 (-1.05%)
DCF (FCF)
$29.26
Tangible Book
$7.38
Graham Number
$23.55
Earnings Power
$17.69

Upcoming Data Readouts (40)

Nov 2026
Est. completion
P1Locally Advanced or Metastatic Solid Tumors
Study of XB010 in Subjects With Solid Tumors
NCT06545331n=396
Dec 2026
Est. completion
P2Metastatic Castration-resistant Prostate Cancer
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06568562n=32
Dec 2026
Est. completion
P2Meningioma
Cabozantinib for Patients With Recurrent or Progressive Meningioma
NCT05425004n=24
Dec 2026
Est. completion
P2Metastatic Renal Cell Carcinoma
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
NCT05263050n=111
Dec 2026
Est. completion
Metastatic Renal Cell Carcinoma
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
NCT04919122n=468
Dec 2026
Est. completion
P2Hepatocellular Carcinoma
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
NCT06698250n=40
Jan 2027
Est. completion
P2Germ Cell Tumor
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
NCT04876456n=50
Feb 2027
Est. completion
P1P2Metastatic Renal Cell Carcinoma
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
NCT06835972n=43
Feb 2027
Est. completion
P2Metastatic Soft-tissue Sarcoma
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
NCT04551430n=105
May 2027
Est. completion
P2Kidney Cancer
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
NCT04322955n=38
May 2027
Est. completion
P1Solid Tumor
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010n=303
Jun 2027
Est. completion
P1Head and Neck Neoplasms
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
NCT06912087n=36
Jul 2027
Est. completion
P2Malignant Neoplasms of Urinary Tract
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
NCT03541902n=32
Nov 2027
Est. completion
P1Metastatic Renal Cell Carcinoma
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
NCT06132945n=2
Nov 2027
Est. completion
P1Ewing Sarcoma
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
NCT06156410n=30
Nov 2027
Est. completion
P1Solid Tumors
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103n=150
Nov 2027
Est. completion
P1Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
NCT04878029n=32
Dec 2027
Est. completion
P1Neuroendocrine Tumors
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
NCT05249114n=6
Dec 2027
Est. completion
P2Brain Metastases
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
NCT05048212n=20
Dec 2027
Est. completion
P2Advanced Renal Cell Carcinoma
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT06863311n=70

Awaiting Results (20)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2026
P2
Cabozantinib in High Grade Neuroendocrine Neoplasms
NCT04412629
Aug 2026
P1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166
Jul 2026
P2
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05502315
Jun 2026
P2
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
NCT04413123
May 2026
P3
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940
Feb 2026
P2
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
NCT04963283
Jul 2025
P3
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673
Jun 2025
P2
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
NCT04289779
Apr 2024
P3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117
Nov 2023
P2
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
NCT04164979

Recent Press Releases